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Background: Dengue virus (DENV), the causative agent of human Dengue hemorrhagic fever, is a mosquito-borne
virus found in tropical and sub-tropical regions around the world. Vaccines against DENV are currently unavailable.
Guanylate-binding protein 1 (GBP1) is one of the Interferon (IFN) stimulated genes (ISGs) and has been shown
important for host immune defense against various pathogens. However, the role of GBP1 during DENV infection
remains unclarified. In this study, we evaluated the relevance of GBP1 to DENV infection in in vitro model.
Findings: Quantitative RT-PCR (qRT-PCR) and Western blot showed that the expression of mouse Gbp1 was
dramatically upregulated in DENV-infected RAW264.7 cells. The intracellular DENV loads were significantly higher in
Gbp1 silenced cells compared with controls. The expression levels of selective anti-viral cytokines were decreased in
Gbp1 siRNA treated cells, while the transcription factor activity of NF-κB was impaired upon GBP1 silencing during
infection.
Conclusions: Our data suggested that GBP1 plays an antiviral role during DENV infection.
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Dengue virus (DENV), a member of the mosquito-borne
flavivirus family, is an icosahedral, enveloped virus with
a single-stranded positive sense RNA genome. Millions
of cases of DENV infection occur worldwide each year
[1,2]. Dengue hemorrhagic fever, the severe form of
DENV infections, can cause serious haemorrhage, sud-
den drop in blood pressure (shock) and even death.
Since no vaccine against DENV is currently available,
much effort is needed to explore the host antiviral
mechanisms for control of DENV infection and vaccine
development [1,3-5].
Interferons (IFNs) are major antiviral cytokines
released by host cells in response to viral and other
pathogenic infections and play crucial roles in induction
and regulation of both innate and adaptive immune
responses [6]. IFNs establish an antiviral state by activat-
ing mainly the Janus kinase/signal transducer and activa-
tor of transcription (JAK/STAT) signaling pathway and* Correspondence: daijianfeng@suda.edu.cn
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reproduction in any medium, provided the orother signaling cascades. Even though hundreds of genes
are characterized as interferon-stimulated genes (ISGs),
the roles of many ISGs during infection remain largely
unknown [7,8].
Guanylate-binding protein 1 (GBP1) is one of the ISGs
that most strongly induced by IFNs [9] and belongs to a
family of GTPases which are divided into three groups:
(1) the large GTPases, also known as GBPs; (2) the small
GTPases; (3) the Mx proteins. The human large GTPase
family is composed of seven members encoded by a gene
cluster located on chromosome 1 [10,11]. The emerging
roles of GBP1 in host immune responses have been
characterized in in vitro and in vivo models [12-15]. For
example, GBP1 is overexpressed in endothelial cells
upon activation of inflammatory cytokines and is
involved in intestinal mucosal inflammation [16]. Re-
cently, a study using Gbp1 knockout mice indicated that
GBP1 has strong anti-bacterial activity [17]. There are
also reports suggesting that GBP1 is involved in host im-
mune response against chlamydia [18] and viruses in-
cluding vesicular stomatitis virus, encephalomyocarditis
virus and Hepatitis C Virus [19-21]. However, the dis-
tinct role of GBP1 during infection of other pathogens,
including mosquito-borne flaviviruses remains largely. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of GBP1 during DENV infection in different in vitro
models.
Gbp1 is upregulated upon DENV infection
Mouse macrophage cell line RAW264.7 can be readily
infected by DENV, and served as an in vitro model for
the study of host innate immune response to DENV. By
using a quantitative RT-PCR (qRT-PCR) based small
cDNA array (SABiosciences, Frederick, MD), we mea-
sured the expression profile of genes from Jak-Stat sig-
naling pathway in DENV (DENV 2, New Guinea C
strain) infected RAW264.7 cells. A number of genes
were found up- or down-regulated upon DENV infec-
tion, as reported in our previous work (Additional file
1of Ref. [22]). Among them, Gbp1 was upregulated 3.97-
fold in DENV infected cells in comparison to uninfected
controls. Independent qRT-PCR and Western blotting
further confirmed the upregulation of GBP1 (mRNA
and protein) upon DENV infection (Figure 1, A and B).
Recent studies have identified host genes that upregu-
lated in human patients with acute DENV infection
[23,24]. GBP1 was one of the genes most highly induced
in patients’ blood cells during early DENV infection
[23], and this is consistent with our result here shown in
in vitro study.
Gbp1 has antiviral activity against DENV infection
To study the specific role of GBP1 during DENV infec-
tion, an siRNA based RNA interference study was per-
formed in RAW264.7 cells. siRNAs specific for Gbp1 or
scrambled control (N.C.) were delivered into RAW264.7
cells respectively via electroporation. 24hrs after siRNA
transfection, cells were challenged by DENV (MOI=1.0)
for another 24hrs. Cells were then harvested and total
RNA and cDNA were made according to standardFigure 1 Gbp1 is upregulated upon DENV infection. A. The gene expre
to mouse beta actin gene. Results are expressed as the mean + the SEM. *
DENV infected cells compared with uninfected cells, as shown in Western blo
results from at least 3 independent experiments.protocols. Gbp1 was silenced efficiently as analyzed by
qRT-PCR (Figure 2A) using gene specific primers
(Table 1) and by Western blot (Figure 2B). The intracel-
lular viral loads, in terms of the transcript levels of the
envelop gene (E), were quantified by qRT-PCR and nor-
malized to mouse beta-actin gene. As shown in Figure 2C,
the DENV viral load was increased 5.0-fold (p<0.05) in
Gbp1 silenced cells compared with control cells. To meas-
ure the production of infectious virus from these cells, a
plaque assay was performed in 293T cells. The titers of
virus in supernatants from Gbp1 silenced cells were about
10- fold higher compared with that from control cells
(Figure 2D). These data suggested that Gbp1 has an anti-
viral activity against DENV in RAW264.7 cells.
Selective cytokines are downregulated in Gbp1 silenced
cells upon DENV infection
In order to examine whether the silencing of Gbp1
would affect the expression of cytokines, the expressions
of some representative cytokines and chemokines were
measured in Gbp1 siRNA or scrambled siRNA treated
cells after DENV infection. Total of six genes were
chosen for the study, including type I interferon (Ifnβ1),
Interleukin-6 (Il6), Chemokine (C-X-C motif ) ligand 1
(Cxcl1), Chemokine (C-X-C motif ) ligand 2(Cxcl2), Che-
mokine (C-C motif ) ligand 5(Ccl5) and C-C chemokine
receptor type 5(Ccr5). Gene specific primers and probe
sets were purchased from Applied Biosystems (Carlsbad,
CA). After DENV infection, the transcription levels of
Ifnβ1, Il6, and Ccl5 in Gbp1 silenced groups were
decreased 2 to 3-fold comparing with controls (p<0.05).
However, transcription levels of Cxcl1/2 and Ccr5 were
not significantly affected (Figure 3, A-F). Consistent with
the mRNA expression, the protein secretion of IFNβ and
IL6 were decreased in Gbp1 silenced cells (Figure 3, G
and H). These data suggested that antiviral role of Gbp1ssion was analyzed by quantitative RT-PCR (qRT-PCR), and normalized
p < 0.05 (t-test). B. The protein level of mouse GBP1 was increased in
t using anti- GBP1 antibody (sc 28579, Santa Cruz, CA). Representative
Figure 2 The viral burden is increased in Gbp1 silenced cells. A-B) RNAi efficiency for Gbp1 as shown in qRT-PCR (A) and Western blot (B).
C-D) DENV burdens in RAW264.7 cells after RNAi silencing. C) The viral burdens were analyzed by measuring the virus E gene copy using
qRT-PCR, and normalized to mouse beta actin gene. D) The titer of infectious DENV in supernatants of cells. Y axis represents the number of
plaques formed in 293T cells when infected with viruses in 100 μl of cell supernatants 24h post infection. Results are expressed as the mean +
the SEM. * p < 0.05 and ** p < 0.01 (t-test). Representative results from at least 3 independent experiments.
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or pro-inflammatory cytokines during DENV infection.
Transcriptional factor activity of NF-κB is impaired in
GBP1 silenced cells
NF-κB (nuclear factor- kappa B) and AP1 (activator pro-













12 ATGCCTTGGTTAGGGGTGACresponse through promoting the transcription of numer-
ous antiviral or pro-inflammatory genes [25,26]. Since
the expression levels of some cytokines were decreased
in Gbp1 silenced cells after DENV infection, we further
measured the activities of NF-κB and AP1 upon GBP1
silencing. 293 cells can be robustly infected by DENV
[27], and are the most common system to measure theNote
siRNA seq for mouse gene Gbp1
siRNA seq for human gene GBP1
Forward primer for qRT-PCR of mouse beta-actin
Reverse primer for qRT-PCR of mouse beta-actin
Forward primer for qRT-PCR of human beta-actin
Reverse primer for qRT-PCR of human beta-actin
Forward primer for qRT-PCR of DENV E gene
Reverse primer for qRT-PCR of DENV E gene
Forward primer for qRT-PCR of mouse Gbp1 gene
Reverse primer for qRT-PCR of mouse Gbp1 gene
Forward primer for qRT-PCR of human GBP1 gene
Reverse primer for qRT-PCR of human GBP1 gene
Figure 3 Cytokine expression in DENV infected cells after gene silencing. A-F) mRNA levels of selective cytokines/chemokines (A:Ifnβ1, B:Il 6,
C:Cxcl1,D:Cxcl2,E:Ccl5,F:Ccr5) were measured by qRT-PCR and normalized to mouse beta-actin gene. G-H) Protein level of IFNβ and IL6 in cell
supernatants. Results are expressed as the mean + the SEM. * p <0.05 (t-test). Representative results from at least 3 independent experiments.
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porter assay. Reporter plasmids pGL- NF-κB, pGL-AP1
and pRL-TK (internal control) (Promega, Madison, MI)
in together with siRNAs specific for human GBP1 or
scrambled control (N.C.), were delivered into 293T cells
respectively by transfection using LipofectamineW LTX
& PLUS (Invitrogen, Grand Island, NY). 24hrs after
transfection, cells were challenged by DENV (MOI=1.0)
for another 24hrs, respectively. RNAi efficiency was con-
firmed by Western blot (Figure 4A). Cells were thenharvested and lysed for dual luciferase reporter assay
(Promega, Madison, MI). The relative activity of NF-κB
was decreased by 40% in GBP1 knockdown cells in com-
parison with controls; while the AP1 activity was not sig-
nificantly impaired in this case (Figure 4, B and C).
These data suggested that GBP1 may influence activity
of NF-κB, thereby contribute to the production of anti-
viral or pro-inflammatory cytokines/chemokines. This
could also partially address the mechanisms of how
GBP1 inhibits DENV replication in cell culture.
Figure 4 NF-κB activity is impaired upon GBP1 silencing. (A) GBP1 was silenced efficiently in 293T cells as shown in western blot. NF-κB (B)
and AP1 (C) activities were measured by dual luciferase reporter assay. (The reporter activities were normalized by internal control (pRL-TK Renilla
luciferase value). The mean value of activities from control cells were set to 1.0) Results are expressed as the mean + the SEM. * p < 0.05 (t-test).
Representative results from at least 3 independent experiments.
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roles of large GTPase family in immune response
[12-14]. GBP1 can be induced by IFNγ as well as IFNα/
β, and its induction can be augmented by TNF-α, IL-1
or LPS[12]. The inhibitory roles of GBP1 to different
pathogens have been reported [17-19,21]. Itsui and his
colleague showed that HCV replication was suppressed
significantly by overexpression of GBP1, while binding
of the HCV-NS5B protein to GBP1 countered the anti-
viral effect through inhibition of GTPase activity [21].
MacMicking speculated that GBP1 might help to limit
the cell-to-cell spread of progeny virus through its anti-
cell proliferative activity [13,28]. GBP1 has modest anti-
viral activity against the negative strand RNA viruses
(such as Rhabdovirus, vesicular stomatitis virus), as well
as the positive strand RNA viruses (Picornovirus and
encephalomyocarditis virus) in cultured cells [19]. In
both anti- chlamydia and antiviral study, the GTPase do-
main of GBP1 was suggested to be critical for its inhibi-
tory activity [18,21]. A recent in vivo study further
suggested that GBPs can solicit host defense proteins,
including the phagocyte oxidase, antimicrobial peptides,
and autophagy effectors, to kill intracellular bacteria
[17]. While, more work are still needed to address the
role and mechanisms of GBP1 in different infection
models especially for viruses.
In this study, we confirmed that GBP1 shows inhibi-
tory effect on DENV infection, influences the activity ofNF-κB and further contributes to the production of anti-
viral and pro-inflammatory cytokine/chemokines. This
could be a novel mechanism for GBP1 to exert its anti-
viral activity in cellular level. Since NF-κB can be acti-
vated upon a broad range of pathogen infection, this
could be a common action for GBP1 to play its role in
different infection models. Further experiments will ad-
dress the detail mechanisms of GBP1 on influencing
NF-κB pathway in various models.
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